Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report specifically addresses the notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance results.
Material Changes
On October 11, 2013, the Administrators of the Deferred Investment Award Programme notified the Company of increases in notional interests in Ordinary Shares for specific individuals. These increases resulted from the re-investment of the dividend paid to shareholders on October 3, 2013, at a price of 1561.75 pence per Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: October 11, 2013.
- Share Price: 1561.75 pence per Share.
- Event: Re-investment of dividends paid on October 3, 2013.
- Individuals Notified: Mr S A Hussain (155.725 shares), Ms E Walmsley (633.212 shares), and Mrs V A Whyte (167.944 shares).
- Financial Data: No financial performance metrics are included in this specific filing.